1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
Vinogradova, O.
Haas, T.
Plow, E.F.
Qin, J.
http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic
1
90.00
90.00
90.00
1.000
1.000
1.000
C6 H15 N4 O2 1
175.209
y
ARGININE
L-peptide linking
C4 H8 N2 O3
132.118
y
ASPARAGINE
L-peptide linking
C4 H7 N O4
133.103
y
ASPARTIC ACID
L-peptide linking
C5 H9 N O4
147.129
y
GLUTAMIC ACID
L-peptide linking
C2 H5 N O2
75.067
y
GLYCINE
peptide linking
C6 H13 N O2
131.173
y
LEUCINE
L-peptide linking
C6 H15 N2 O2 1
147.195
y
LYSINE
L-peptide linking
C9 H11 N O2
165.189
y
PHENYLALANINE
L-peptide linking
C5 H9 N O2
115.130
y
PROLINE
L-peptide linking
C5 H11 N O2
117.146
y
VALINE
L-peptide linking
US
Proc.Natl.Acad.Sci.USA
PNASA6
0040
0027-8424
97
1450
1455
10.1073/pnas.040548197
10677482
A structural basis for integrin activation by the cytoplasmic tail of the alpha IIb-subunit.
2000
10.2210/pdb1dpk/pdb
pdb_00001dpk
1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
2395.579
INTEGRIN ALPHA-IIB SUBUNIT
CYTOPLASMIC DOMAIN
1
syn
polymer
no
no
KVGFFKRNRPPLEEDDEEGE
KVGFFKRNRPPLEEDDEEGE
A
polypeptide(L)
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
database_2
pdbx_nmr_exptl_sample_conditions
pdbx_nmr_software
pdbx_struct_assembly
pdbx_struct_oper_list
repository
Initial release
Version format compliance
Version format compliance
Data collection
Database references
Derived calculations
Experimental preparation
1
0
2000-02-28
1
1
2008-04-27
1
2
2011-07-13
1
3
2022-02-16
_database_2.pdbx_DOI
_database_2.pdbx_database_accession
_pdbx_nmr_exptl_sample_conditions.pressure_units
_pdbx_nmr_software.name
SOLUTION STRUCTURE OF THE CONSTITUTIVELY ACTIVE MUTANT OF THE INTEGRIN ALPHA IIB CYTOPLASMIC DOMAIN.
RCSB
Y
RCSB
1999-12-27
REL
The peptide was chemically synthesized. The sequence of residues is naturally found in the platelets of homo sapiens (human).
sample
USED DPC (DODECYL-PHOSPHOCHOLINE) MICELLES
back calculated data agree with experimental NOESY spectrum
30
16
2D NOESY
DQF-COSY
2D TOCSY
50 mM NACL
5.0
1
atm
298
K
simulated annealing
1
minimized average structure
3MM PEPTIDE
VARIAN
collection
VNMR
5.5
DELAGLIO, F.
processing
NMRPipe
GARRETT, D.S.
data analysis
PIPP
BRUNGER, A.T.
structure solution
X-PLOR
3.2
BRUNGER, A.T.
refinement
X-PLOR
3.2
500
Varian
UNITYPLUS
LYS
1
n
1
LYS
1
A
VAL
2
n
2
VAL
2
A
GLY
3
n
3
GLY
3
A
PHE
4
n
4
PHE
4
A
PHE
5
n
5
PHE
5
A
LYS
6
n
6
LYS
6
A
ARG
7
n
7
ARG
7
A
ASN
8
n
8
ASN
8
A
ARG
9
n
9
ARG
9
A
PRO
10
n
10
PRO
10
A
PRO
11
n
11
PRO
11
A
LEU
12
n
12
LEU
12
A
GLU
13
n
13
GLU
13
A
GLU
14
n
14
GLU
14
A
ASP
15
n
15
ASP
15
A
ASP
16
n
16
ASP
16
A
GLU
17
n
17
GLU
17
A
GLU
18
n
18
GLU
18
A
GLY
19
n
19
GLY
19
A
GLU
20
n
20
GLU
20
A
author_defined_assembly
1
monomeric
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
1_555
x,y,z
identity operation
0.0000000000
0.0000000000
0.0000000000
1
A
A
O
HD22
PHE
ASN
4
8
1.55
2
A
A
O
HD22
PHE
ASN
4
8
1.46
3
A
A
O
HD22
PHE
ASN
4
8
1.56
4
A
A
O
HD22
PHE
ASN
4
8
1.48
6
A
A
O
HD22
PHE
ASN
4
8
1.46
7
A
A
O
HD22
PHE
ASN
4
8
1.54
8
A
A
O
HD22
PHE
ASN
4
8
1.46
8
A
A
O
O
ARG
GLU
9
13
2.14
9
A
A
O
HD22
PHE
ASN
4
8
1.50
11
A
A
O
HD22
PHE
ASN
4
8
1.55
12
A
A
HZ2
OD1
LYS
ASP
6
16
1.40
12
A
A
O
HD22
PHE
ASN
4
8
1.47
13
A
A
O
HD22
PHE
ASN
4
8
1.47
14
A
A
O
HD22
PHE
ASN
4
8
1.46
15
A
A
O
HD22
PHE
ASN
4
8
1.53
16
A
A
O
HD22
PHE
ASN
4
8
1.56
1
A
VAL
2
-160.94
27.26
1
A
PHE
4
-142.64
13.99
1
A
PHE
5
-140.55
-38.88
1
A
LYS
6
-79.38
20.12
1
A
ARG
7
-131.10
-62.31
1
A
PRO
11
-59.20
-71.26
1
A
LEU
12
-41.79
-87.34
1
A
ASP
15
-93.27
-79.37
1
A
GLU
18
-48.29
-80.91
2
A
VAL
2
-161.09
27.64
2
A
PHE
5
-136.71
-40.19
2
A
ARG
7
-129.01
-61.84
2
A
PRO
11
-54.06
-71.10
2
A
LEU
12
-41.16
-92.09
2
A
ASP
15
-93.37
-78.21
2
A
GLU
17
-60.26
96.69
3
A
VAL
2
-160.75
24.42
3
A
PHE
5
-139.88
-37.62
3
A
LYS
6
-79.23
20.05
3
A
ARG
7
-131.48
-62.09
3
A
PRO
11
-56.89
-72.42
3
A
LEU
12
-38.90
-89.21
3
A
ASP
15
-93.36
-102.52
4
A
VAL
2
-158.08
27.36
4
A
PHE
5
-138.95
-37.93
4
A
LYS
6
-79.10
21.57
4
A
ARG
7
-131.87
-61.45
4
A
PRO
11
-57.82
-71.23
4
A
LEU
12
-40.78
-88.34
4
A
ASP
15
-92.51
-78.61
5
A
VAL
2
-160.90
24.19
5
A
PHE
5
-140.86
-38.06
5
A
ARG
7
-130.48
-61.63
5
A
PRO
11
-56.66
-71.84
5
A
LEU
12
-42.97
-89.75
5
A
ASP
15
-91.44
-79.24
5
A
ASP
16
-49.80
163.34
5
A
GLU
17
-67.61
84.19
6
A
VAL
2
-158.21
27.63
6
A
PHE
5
-135.39
-36.54
6
A
LYS
6
-78.67
20.47
6
A
ARG
7
-131.96
-63.03
6
A
PRO
11
-59.10
-71.09
6
A
LEU
12
-41.20
-87.34
6
A
ASP
15
-89.68
-77.34
7
A
VAL
2
-158.20
27.41
7
A
PHE
5
-138.52
-37.56
7
A
LYS
6
-78.96
20.38
7
A
ARG
7
-130.68
-61.75
7
A
PRO
11
-57.88
-72.17
7
A
LEU
12
-42.60
-90.28
7
A
ASP
15
-92.73
-78.82
8
A
VAL
2
-158.36
27.80
8
A
PHE
5
-135.31
-36.59
8
A
LYS
6
-78.47
20.28
8
A
ARG
7
-131.47
-62.92
8
A
PRO
11
-61.86
-72.20
8
A
LEU
12
-43.16
-78.60
8
A
ASP
15
-95.50
-79.16
9
A
VAL
2
-158.43
27.06
9
A
PHE
5
-135.29
-36.03
9
A
ARG
7
-130.77
-63.64
9
A
PRO
11
-58.96
-72.67
9
A
LEU
12
-37.96
-88.77
9
A
ASP
15
-88.53
-102.24
10
A
VAL
2
-160.90
24.18
10
A
PHE
5
-140.91
-38.02
10
A
ARG
7
-130.60
-61.68
10
A
PRO
11
-56.85
-71.74
10
A
LEU
12
-42.99
-90.14
10
A
ASP
15
-91.56
-79.27
10
A
GLU
17
-68.68
91.20
10
A
GLU
18
-46.29
-79.24
11
A
VAL
2
-160.77
22.66
11
A
PHE
5
-140.67
-39.63
11
A
LYS
6
-79.39
21.92
11
A
ARG
7
-130.39
-60.99
11
A
PRO
11
-56.47
-70.91
11
A
LEU
12
-42.55
-87.90
11
A
ASP
15
-93.03
-77.92
11
A
GLU
18
-48.65
-75.59
12
A
VAL
2
-158.09
28.04
12
A
PHE
5
-137.26
-37.52
12
A
LYS
6
-78.92
24.50
12
A
ARG
7
-136.10
-63.16
12
A
PRO
11
-60.24
-71.73
12
A
LEU
12
-36.37
-86.39
12
A
GLU
14
-69.94
74.49
12
A
ASP
15
-90.42
-102.47
12
A
GLU
17
-59.96
109.41
13
A
VAL
2
-160.80
24.21
13
A
PHE
5
-137.30
-38.29
13
A
ARG
7
-130.38
-61.25
13
A
PRO
11
-58.65
-72.23
13
A
LEU
12
-41.19
-92.31
13
A
ASP
15
-91.73
-80.43
14
A
VAL
2
-158.32
27.58
14
A
PHE
5
-135.64
-36.54
14
A
ARG
7
-131.13
-62.74
14
A
PRO
11
-59.72
-70.84
14
A
LEU
12
-43.55
-84.30
14
A
ASP
15
-90.88
-77.58
14
A
GLU
18
-49.68
-73.85
15
A
VAL
2
-160.98
23.26
15
A
PHE
5
-140.78
-38.74
15
A
ARG
7
-130.69
-61.87
15
A
PRO
11
-56.67
-72.52
15
A
LEU
12
-41.04
-90.33
15
A
ASP
15
-93.46
-78.92
15
A
GLU
17
-68.83
91.57
16
A
VAL
2
-160.82
24.36
16
A
PHE
5
-139.95
-37.69
16
A
ARG
7
-131.14
-61.52
16
A
PRO
11
-57.62
-71.93
16
A
LEU
12
-42.31
-91.00
16
A
ASP
15
-91.20
-79.67
minimized average
SOLUTION STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE INTEGRIN ALPHA-IIB SUBUNIT
1
N
N
A
ASN
8
A
ASN
8
HELX_P
A
GLU
13
A
GLU
13
1
1
6
CELL ADHESION
HELIX-TURN, CELL ADHESION
ITA2B_HUMAN
UNP
1
P08514
1020
1039
1DPK
1
20
P08514
A
1
1
20
1
P 1